Related Experiment Video

Updated: Nov 19, 2025

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
04:56

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients

Published on: August 4, 2023

1.0K

COVID-19 With Preexisting Hypercoagulability Digestive Disease

Mingshan Jiang1,2,3, Jingxi Mu1,2,3, Silan Shen1,2,3

  • 1Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu, China.

Frontiers in Medicine
|February 1, 2021
PubMed

Insights

Coronavirus disease 2019 (COVID-19) causes hypercoagulability, increasing risks for blood clots. This review covers COVID-19

Area of Science:

  • Medical Science
  • Virology
  • Hematology

Background:

  • Coronavirus disease 2019 (COVID-19) presents a global health and economic challenge.
  • Hypercoagulability and thrombotic complications significantly impact COVID-19 patient outcomes.
  • Preexisting digestive conditions may interact with COVID-19's hypercoagulable state.

Purpose of the Study:

  • To review clinical findings, pathogenesis, and therapeutic strategies for hypercoagulability in COVID-19.
  • To specifically examine thromboembolism in COVID-19 patients with pre-existing digestive hypercoagulability disorders.

Main Methods:

  • Literature review of clinical findings.
  • Analysis of potential underlying pathogenesis.
  • Evaluation of current therapeutic strategies.

Main Results:

  • COVID-19 is strongly associated with hypercoagulability and thromboembolic events.
  • Understanding the pathogenesis is crucial for effective treatment.
  • Therapeutic strategies are evolving to manage these complications.

Conclusions:

  • Hypercoagulability is a key feature of severe COVID-19, affecting prognosis.
  • Targeted therapies are needed for thromboembolism in COVID-19.
  • Further research is warranted for patients with co-existing digestive diseases.

Keywords:
SARS-CoV-2coronavirus disease 2019hypercoagulabilityinflammatory bowel diseasethromboembolism

More Related Videos

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States07:09

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States

Published on: April 1, 2015

11.8K
Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models04:40

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models

Published on: January 5, 2024

2.8K

Related Concept Videos

Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.6K
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
121
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.6K
Other Disorders of Digestive System01:30

Other Disorders of Digestive System

The gastrointestinal tract is susceptible to various disorders. If the lower esophageal sphincter is damaged, stomach acid can flow back into the esophagus, causing irritation and inflammation of the lining. This condition is called gastroesophageal reflux disease (known as heartburn) and may cause chest pain and difficulty swallowing. In the stomach, prolonged use of nonsteroidal anti-inflammatory drugs like aspirin, chronic alcohol consumption, bacterial infections such as Helicobacter...
1.2K
Peptic Ulcer Disease II: Pathophysiology01:28

Peptic Ulcer Disease II: Pathophysiology

Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
1.4K
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
867